Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus Aug 12, 2010: Clinical and Regulatory PCR and Nucleic Acid Testing News

Premium

Myconostica said this week that its MycAssay Aspergillus and MycAssay Pneumocystis have received CE marking on the Roche LightCycler 2.0 and Stratagene Mx3000 series platforms.

The CE marking on these two platforms is in addition to existing CE marks for the tests on the Cepheid SmartCycler and Life Technologies Applied Biosystems 7500, Manchester, UK-based Myconostica said.

MycAssay Aspergillus detects Aspergillus spp. DNA in lower respiratory tract samples. Meantime, the MycAssay Pneumocystis detects Pneumocystis jirovecii DNA in lower respiratory tract samples. Both assays are designed to be used by qualified laboratory professionals and to aid physicians in diagnosing patients.

When used in conjunction with Myconostica's fungal DNA extraction system, MycXtra, a result can be obtained within three hours of sample receipt, Myconostica said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.